Drug Profile
Stem cell therapy - Xintela
Alternative Names: XSTEM-VLULatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Xintela
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Leg ulcer
- No development reported Cartilage disorders; Osteoarthritis
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Osteoarthritis in Sweden (Intra-articular)
- 05 Jul 2022 Phase-I/II clinical trials in Leg ulcer in Sweden (Topical) (EudraCT2022-000492-39)
- 28 May 2020 No recent reports of development identified for preclinical development in Cartilage-disorders in Sweden (Intra-articular, Injection)